Selegiline
Borderline Personality Disorder
Mood and Anxiety Research, IncSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Borderline Personality Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LITHIUM, ELEMENTAL Columbia Northwest Pharmaceuticals | Phase 2 | B |
TEONANACATL University of Chicago | Phase 2 | B |
CITALOPRAM Columbia Northwest Pharmaceuticals | Phase 2 | B |
Midazolam Joshua Rosenblat | Phase 2 | CCC |
Escitalopram University of Chicago | Phase 2 | CCC |
View all 9 →
Same molecule, other indications
Selegiline is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →